Literature DB >> 16893405

Intravenous iron therapy in end-stage renal disease.

Ursula C Brewster1.   

Abstract

Intravenous iron therapy is instrumental in the management of anemia in patients with end-stage renal disease (ESRD). Iron is available in several different preparations, with slight differences in the pharmacology of each. Given the importance of intravenous iron in the management of these patients, clinicians should be aware of the potential risks associated with it. Intravenous iron has effects on host immunity that raise concerns about clinical infection risk. Iron preparations appear to increase oxidative stress in these patients, which has important implications for cardiovascular disease states. Lastly, the effects of intravenous iron on liver disease are largely unknown.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16893405     DOI: 10.1111/j.1525-139X.2006.00174.x

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  8 in total

1.  What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: Balancing Benefits and Safety with Intravenous Iron Treatment.

Authors:  M Alan Brookhart; Xiaojuan Li; Abhijit V Kshirsagar
Journal:  Semin Dial       Date:  2016-10-20       Impact factor: 3.455

Review 2.  Safety of intravenous iron in hemodialysis patients.

Authors:  Xiaojuan Li; Abhijit V Kshirsagar; M Alan Brookhart
Journal:  Hemodial Int       Date:  2017-04-03       Impact factor: 1.812

Review 3.  Iron and infection in hemodialysis patients.

Authors:  Julie H Ishida; Kirsten L Johansen
Journal:  Semin Dial       Date:  2013-12-12       Impact factor: 3.455

4.  Pretransplantation erythropoiesis-stimulating agent hyporesponsiveness is associated with increased kidney allograft failure and mortality.

Authors:  Nadiesda A Costa; Abhijit V Kshirsagar; Lily Wang; Randal K Detwiler; M Alan Brookhart
Journal:  Transplantation       Date:  2013-11-15       Impact factor: 4.939

5.  Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients.

Authors:  M Alan Brookhart; Janet K Freburger; Alan R Ellis; Lily Wang; Wolfgang C Winkelmayer; Abhijit V Kshirsagar
Journal:  J Am Soc Nephrol       Date:  2013-06-20       Impact factor: 10.121

6.  Comparative Evaluation of U.S. Brand and Generic Intravenous Sodium Ferric Gluconate Complex in Sucrose Injection: Biodistribution after Intravenous Dosing in Rats.

Authors:  Christopher R Beekman; Murali Matta; Christopher D Thomas; Adil Mohammad; Sharron Stewart; Lin Xu; Ashok Chockalingam; Katherine Shea; Dajun Sun; Wenlei Jiang; Vikram Patel; Rodney Rouse
Journal:  Nanomaterials (Basel)       Date:  2017-12-28       Impact factor: 5.076

7.  Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients.

Authors:  Abhijit V Kshirsagar; Janet K Freburger; Alan R Ellis; Lily Wang; Wolfgang C Winkelmayer; M Alan Brookhart
Journal:  PLoS One       Date:  2013-11-01       Impact factor: 3.240

8.  Comparative short-term safety of bolus versus maintenance iron dosing in hemodialysis patients: a replication study.

Authors:  Janet K Freburger; Alan R Ellis; Abhijit V Kshirsagar; Lily Wang; M Alan Brookhart
Journal:  BMC Nephrol       Date:  2014-09-22       Impact factor: 2.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.